Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.49 |
| ▸ | NQO1 | P15559 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PTAFR | P25105 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1941564 | 0.86 | PKM (0.48) | NQO1MAPTALDH1A1NPSR1ALOX15 | |
| SCHEMBL24510994 | 0.84 | PTGS2 (0.52) | NQO1MAPTALDH1A1NPSR1LMNA | |
| SCHEMBL15345666 | 0.82 | HTR2A (0.46) | NQO1MAPTALDH1A1NPSR1LMNA | |
| SCHEMBL6615163 | 0.79 | NQO1 (0.43) | NQO1L3MBTL1MAPTALDH1A1NPSR1 | |
| SCHEMBL11741652 | 0.79 | NQO1 (0.43) | NQO1MAPTALDH1A1NPSR1LMNA | |
| SCHEMBL6041292 | 0.79 | TTR (0.45) | TTRNQO1ALDH1A1LMNAHPGD | |
| SCHEMBL6041334 | 0.78 | MRGPRX4 (0.47) | L3MBTL1MAPTALDH1A1NPSR1LMNA | |
| SCHEMBL11478661 | 0.76 | HPGD (0.48) | L3MBTL1MAPTALDH1A1NPSR1HPGD | |
| Hydrochloric Acid SCHEMBL5962932 | 0.76 | HTR2A (0.53) | — | |
| SCHEMBL8197756 | 0.75 | NQO1 (0.54) | NQO1MAPTALDH1A1NPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1175400-B1 | RENIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-06-15 | — | — | EP | disclosed |
| US-6673931-B2 | (4-(4-(3-(2-METHOXY-BENZYLOXY)-PROPOXY)-PHENYL)-5-(4-METHOXY -NAPHTHALEN-2-YLMETHOXY)-PIPERIDIN-3-YL)-METHANOL FOR EXAMPLE; USE TREATING RESTENOSIS, GLAUCOMA, CARDIAC AND KIDNEY INSUFFICIENCY | HOFFMAN-LA ROCHE INC. | 2004-01-06 | — | — | US | disclosed |
| US-20020087002-A1 | Naphthalenyl piperidines as renin inhibitors | NOVARTIS AG (CH) | 2002-07-04 | — | — | US | disclosed |
| US-6376672-B1 | RESTENOSIS; VISION DEFECTS; CARDIOVASCULAR DISORDERS; KIDNEY DIEASES | HOFFMANN-LA ROCHE INC. | 2002-04-23 | — | — | US | disclosed |
| EP-1175400-A1 | RENIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000064873-A1 | RENIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020087002-A1 | Naphthalenyl piperidines as renin inhibitors | REN, TNNI3, PTGIS | TTR 3361/4885NQO1 240/4885L3MBTL1 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.